Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Moderna (MRNA)
NASDAQ:MRNA
Moderna (MRNA) Stock Price & Analysis
15,398 Followers
MRNA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$62.55 - $170.47
Previous Close$118.19
Volume2.64M
Average Volume (3M)3.96M
Market Cap
$45.30B
Enterprise Value$37.98B
Total Cash (Recent Filing)$8.52B
Total Debt (Recent Filing)$1.21B
Price to Earnings (P/E)―
Beta1.05
Next Earnings
Aug 01, 2024EPS Estimate
-$3.35Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-15.68
Shares Outstanding383,239,726
10 Day Avg. Volume3,540,197
30 Day Avg. Volume3,962,692
Standard Deviation0.26
R-Squared0.10
Alpha0.04
Financial Highlights & Ratios
Price to Book (P/B)3.72
Price to Sales (P/S)7.57
Price to Cash Flow (P/CF)20.60
P/FCF Ratio31.30
Enterprise Value/Market CapN/A
Enterprise Value/Revenue7.37
Enterprise Value/Gross Profit18.43
Enterprise Value/Ebitda-9.01
Forecast
1Y Price Target
$144.71Price Target Upside20.19% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering18
Moderna News
PremiumStock Analysis & Ideas
Moderna Stock (NASDAQ:MRNA): Next-Gen COVID-19 Vaccine Is More Than a Rehash
PremiumCompany Announcements
Moderna Reshuffles Board, Adds Carlyle Co-Founder
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessThe phase 2b trial found that mRNA-4157, in combination with Keytruda (standard of care treatment), significantly reduced the risk of melanoma recurrence, distant metastasis, and death.
Safety ProfileNo GBS cases deemed related to mRESVIA have occurred to date, making mRESVIA one of the safest amongst peers to date.
Vaccine ApprovalModerna recently had its second-ever product approved, as the FDA approved mRESVIA, an mRNA respiratory syncytial virus (RSV) vaccine, to protect adults aged 60 years and older from lower respiratory tract disease caused by RSV infection.
Bears Say
COVID-19 Vaccine SegmentThe downward trend of the COVID-19 vaccine segment appears to continue as the demand for boosters also sink.
Revenue And EarningsThe EPS for 2024 is projected to decline significantly according to the latest consensus estimates.
RSV Vaccine MarketStock is down 10% due to ACIP's more stringent recommendation on RSV vaccines going into the 2024-25 season.
---
Ownership Overview
14.73% Insiders
21.35% Mutual Funds
34.98% Other Institutional Investors
28.94% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
MRNA FAQ
What was Moderna’s price range in the past 12 months?
Moderna lowest stock price was $62.55 and its highest was $170.47 in the past 12 months.
What is Moderna’s market cap?
Currently, no data Available
When is Moderna’s upcoming earnings report date?
Moderna’s upcoming earnings report date is Aug 01, 2024 which is in 6 days.
How were Moderna’s earnings last quarter?
Moderna released its earnings results on May 02, 2024. The company reported -$3.07 earnings per share for the quarter, beating the consensus estimate of -$3.557 by $0.487.
Is Moderna overvalued?
According to Wall Street analysts Moderna’s price is currently Undervalued.
Does Moderna pay dividends?
Moderna does not currently pay dividends.
What is Moderna’s EPS estimate?
Moderna’s EPS estimate is -$3.35.
How many shares outstanding does Moderna have?
Moderna has 383,239,720 shares outstanding.
What happened to Moderna’s price movement after its last earnings report?
Moderna reported an EPS of -$3.07 in its last earnings report, beating expectations of -$3.557. Following the earnings report the stock price went up 12.677%.
Which hedge fund is a major shareholder of Moderna?
Among the largest hedge funds holding Moderna’s share is Flagship Pioneering Inc.. It holds Moderna’s shares valued at 1B.
---
Moderna Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$144.71 (20.19% Upside)
$144.71 (20.19% Upside)
Blogger Sentiment
Neutral
MRNA Sentiment 58%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 2.3M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $30.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▲ 0.1%
Last 30 Days ▼ 0.3%
Last 30 Days ▼ 0.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-3.91%
12-Months-Change
Fundamentals
Return on Equity
-37.68%
Trailing 12-Months
Asset Growth
-30.66%
Trailing 12-Months
Company Description
Moderna
Incorporated in 2010, Massachusetts-based Moderna, Inc. is a clinical stage biotechnology company which develops therapeutics and vaccines based on messenger ribonucleic acid (mRNA) for the treatment of infectious diseases, immuno-oncology, rare diseases, and cardiovascular diseases. Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics.
---
MRNA Company Deck
---
MRNA Earnings Call
Q1 2024
0:00 / 0:00
---
MRNA Revenue Breakdown
52.54% Rest of World
27.67% U.S.
19.79% Europe
---
MRNA Stock 12 Month Forecast
Average Price Target
$144.71
▲(20.19% Upside)
Technical Analysis
Best Analysts Covering MRNA
1 Year
1 Year Success Rate
25/27 ratings generated profit
1 Year Average Return
+249.86%
assigned a buy rating last month
Copying Hartaj Singh's trades and holding each position for 1 Year would result in 92.59% of your transactions generating a profit, with an average return of +249.86% per trade.
---